Bruising

Corrective camouflage of macular ecchymosis of the antecubital fossa following venous blood draws

Patient photographs

Before After

Description of the disease

Cancer therapies using immune checkpoint inhibitors aim to restore the anti-tumour immune functions of T lymphocytes. Monoclonal antibodies (against CTLA-4 and PD-1/PD-L1) currently available for the treatment of advanced melanoma are administered by slow intravenous infusion every 2, 3 or 4 weeks, depending on the drug and dosage. In addition, patients receiving these therapies must undergo frequent blood tests prior to infusions to monitor for immune-related adverse events (irAEs) that may be associated with these therapies.

Dermocosmetic management